Screening of E. coli β-clamp Inhibitors Revealed that Few Inhibit Helicobacter pylori More Effectively: Structural...

Area of Science:

• Microbiology
• Drug Discovery
• Biochemistry

Background:

• The beta-clamp is crucial for DNA replication and a significant drug target.
• Helicobacter pylori possesses unique DNA replication machinery, differing from other microbes.
• Investigating drug response differences between H. pylori and E. coli due to protein variations is essential.

Purpose of the Study:

• To evaluate the efficacy of E. coli beta-clamp inhibitors against H. pylori beta-clamp.
• To determine if structural differences in H. pylori DNA replication proteins affect drug response.
• To explore the development of species-specific drugs for H. pylori infections.

Main Methods:

• Molecular docking and surface competition assays were used to screen inhibitors.
• Co-crystallization was performed to determine the binding structures of inhibitors with H. pylori beta-clamp.
• Antimicrobial assays were conducted to assess growth inhibition and minimum inhibitory concentrations (MIC).

Main Results:

• Three inhibitors (5-chloroisatin, carprofen, 3,4-difluorobenzamide) successfully co-crystallized with H. pylori beta-clamp, binding at the protein-protein interaction site.
• 5-chloroisatin and 3,4-difluorobenzamide demonstrated significant H. pylori growth inhibition in vivo, with MICs in the micromolar range.
• These compounds showed better inhibitory effects against H. pylori than against E. coli.

Conclusions:

• The study validates H. pylori beta-clamp as a viable drug target.
• 5-chloroisatin and 3,4-difluorobenzamide show potential as leads for developing novel H. pylori-specific antimicrobial agents.
• Further research can focus on creating species-specific pharmacophores for targeted H. pylori drug development.